Here are five key notes on nine orthopedic device companies based on their first quarter financial report.
Percent changes are indicate year-over-year increases or decreases for the quarter. The companies are arranged by quarterly net sales or revenue, from highest to lowest.
Medtronic (3rd quarter fiscal year results)
1. Revenue: $7.3 billion (5 percent increase)
2. U.S. revenue: $4.1 billion (4 percent increase)
3. Spine revenue: $657 million (3 percent increase)
4. Pain therapies revenue: $272 million (3 percent decrease)
5. Brain therapies revenue: $518 million (7 percent increase)
1. Net sales: $2.96 billion (18.4 percent increase)
2. Net earnings: $444 million (10.4 percent increase)
3. Medsurg net sales: $1.31 billion (36.2 percent increase)
4. Orthopedics net sales: $1.14 billion (7.4 percent increase)
5. Neurotechnology and spine net sales: $520 million (7.3 percent increase)
1. Net sales: $2.3 billion (0.7 percent decrease)
2. U.S. net sales: $1.3 billion (0.9 percent decrease)
3. Knee net sales: $398 million (2.3 percent increase)
4. Trauma net sales: $642 million (flat)
5. Spine and other net sales: $933 million (3.6 percent decrease)
1. Net sales: $1.98 billion (3.8 percent increase)
2. Net earnings: $299.4 million (175.2 percent increase)
3. Knee sales $702 million (0.2 percent decrease)
4. Hip sales: $475 million (1.7 percent decrease)
5. Spine and CMF: $186 million (32 percent increase)
1. Revenue: $1.1 billion (flat)
2. U.S. revenue: $555 million (1 percent decrease)
3. Sports medicine, trauma and other revenue: $466 million (flat)
4. Joint reconstruction: $396 million (1 percent decrease)
5. Advanced wound management: $280 million (1 percent decrease)
1. Revenue: $250 million (16.2 percent increase)
2. Net income: $12.8 million
3. Operating expenses: $165 million
4. Cash, cash equivalents and short and long term marketable securities: $134 million
5. Operating profit margin: 9.3 percent
1. Sales: $155.8 million (11.9 percent increase)
2. Net income: $28.7 million
3. U.S. sales: $129 million
4. Innovative fusion sales: $81.8 million
5. Disruptive technology: $73.9 million
1. Net sales: $102.7 million (4.1 percent increase)
2. Net loss: $2.3 million
3. Spine sales: $19.3 million (2.3 percent increase)
4. Biologic sales: $15 million (6.3 percent increase)
5. BioStim sales: $44.5 million (8.5 percent increase)
1. Revenue: $61.9 million (9.9 percent increase)
2. Net loss: $10.9 million
3. U.S. revenue: $46.2 million (up 9.5 percent)
4. International revenue: $15.7 million (11.1 percent increase)
5. Adjusted EBITDA: $300,000